Wu et al., 2013 [81] | TNF inhibitor (etanercept or monoclonal antibody) | Myocardial infarction | Etanercept: 976; Monoclonal antibody: 217; Topical therapy: 5075 | Hazard ratio (compared to topical agents): Etanercept: 0.53 (95% CI 0.31 - 0.92); Monoclonal antibody: 0.25 (95% CI 0.06 - 1.03) | United States/ Retrospective cohort study |
Wu et al., 2014 [82] | TNF inhibitor | Myocardial infarction | Psoriasis (treated with TNF inhibitor): 846; Psoriasis (not treated with TNF inhibitor): 7172 | Hazard ratio (compared to psoriasis patients not treated with TNF inhibitors): 0.26 (95% CI 0.12 - 0.56) | United States/ Retrospective cohort study |
Wu et al., 2017 [83] | TNF inhibitor | Major cardiovascular events (myocardial infarction, stroke or transient ischemic attack, unstable angina) | TNF inhibitor: 9148; Methotrexate: 8581 | Hazard ratio (compared to methotrexate): Major cardiovascular event: 0.55 (95% CI 0.45 - 0.67) Myocardial infarction: 0.49 (95% CI 0.34 - 0.71); Stroke or TIA: 0.55 (95% CI 0.42 - 0.71); Unstable angina: 0.58 (95% CI 0.41 - 0.82) | United States/ Retrospective cohort study |